Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma

Area of Science:

• Oncology
• Thyroid Cancer Research
• Pharmacological Therapy

Background:

• Anaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy with a poor prognosis.
• Limited randomized controlled trials exist for metastatic ATC, necessitating exploration of novel therapeutic strategies.
• Lenvatinib (a tyrosine kinase inhibitor) and pembrolizumab (an immune checkpoint inhibitor) are emerging treatments for ATC.

Purpose of the Study:

• To review the preclinical rationale for using lenvatinib and pembrolizumab individually and in combination for metastatic ATC.
• To evaluate the clinical evidence supporting the efficacy and safety of the lenvatinib-pembrolizumab association in ATC.
• To discuss potential predictive biomarkers for treatment response.

Main Methods:

• Literature review of preclinical studies on lenvatinib and pembrolizumab in ATC.
• Analysis of clinical trial data and case reports on immunotherapy, lenvatinib, and the combination therapy in ATC.
• Examination of safety profiles and biomarker research related to the drug association.

Main Results:

• Preclinical data suggest synergistic effects between lenvatinib and pembrolizumab.
• Clinical evidence indicates potential efficacy of the combination, leading to its off-label use.
• Safety data and potential predictive biomarkers are being investigated.

Conclusions:

• The combination of lenvatinib and pembrolizumab presents a promising therapeutic option for metastatic ATC.
• Further research is needed to establish optimal use, confirm efficacy through robust trials, and identify predictive biomarkers.
• Understanding the synergistic mechanisms and safety is crucial for advancing ATC treatment.